Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Pancreatic Cancer | Research

E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1

Authors: Xueqiang Deng, Xiaowei Fu, Hong Teng, Lu Fang, Bo Liang, Rengui Zeng, Lian Chen, Yeqing Zou

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Pancreatic cancer (PC) is one of the most fatal digestive system cancers. tripartite motif-29 (TRIM29) has been reported as oncogene in several human cancers. However, the precise role and underlying signal cascade of TRIM29 in PC progression remain unclear.

Methods

Western blot, qRT-PCR and immunohistochemistry were used to analyze TRIM29 and Yes-associated protein 1 (YAP1) levels. CCK8 assays, EdU assays and flow cytometry were designed to explore the function and potential mechanism of TRIM29 and YAP1 in the proliferation of PC. Next, a nude mouse model of PC was established for validating the roles of TRIM29 and YAP1 in vivo. The relationship among TRIM29 and YAP1 was explored by co-immunoprecipitation and in vitro ubiquitination assay.

Results

TRIM29 and YAP1 was significantly upregulated in PC patient samples, and TRIM29 expression was closely related to a malignant phenotype and poorer overall survival (OS) of PC patients. Functional assays revealed that TRIM29 knockdown suppresses cell growth, arrests cell cycle progression and promotes cell apoptosis of PC cells in vivo and in vitro. Furthermore, the rescue experiments demonstrated that TRIM29-induced proliferation is dependent on YAP1 in PC cells. Mechanistically, TRIM29 regulates YAP1 expression by directly binding to YAP1, and reduced its ubiquitination and degradation.

Conclusion

Taken together, these results identify a novel mechanism used by PC growth, and provide insight regarding the role of TRIM29 in PC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chari ST, Sharma A, Maitra A. Early detection of sporadic pancreatic ductal adenocarcinoma: problems, promise, and prospects. Ann Intern Med. 2020;172(8):558–9.CrossRef Chari ST, Sharma A, Maitra A. Early detection of sporadic pancreatic ductal adenocarcinoma: problems, promise, and prospects. Ann Intern Med. 2020;172(8):558–9.CrossRef
2.
go back to reference Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, Ng K, Chong C, Zheng ZJ, Wong MC. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2020;38(6):3481–8. Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, Ng K, Chong C, Zheng ZJ, Wong MC. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2020;38(6):3481–8.
3.
go back to reference Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403.CrossRef Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403.CrossRef
4.
go back to reference Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T, Chayama K. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol. 2008;33(6):1187–94.PubMed Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T, Chayama K. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol. 2008;33(6):1187–94.PubMed
5.
go back to reference Tan ST, Liu SY, Wu B. TRIM29 overexpression promotes proliferation and survival of bladder cancer cells through NF-kappaB Signaling. Cancer Res Treat. 2016;48(4):1302–12.CrossRef Tan ST, Liu SY, Wu B. TRIM29 overexpression promotes proliferation and survival of bladder cancer cells through NF-kappaB Signaling. Cancer Res Treat. 2016;48(4):1302–12.CrossRef
6.
go back to reference Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42(4):297–311.CrossRef Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42(4):297–311.CrossRef
7.
go back to reference Ohmine S, Sakuma R, Sakuma T, Thatava T, Takeuchi H, Ikeda Y. The antiviral spectra of TRIM5alpha orthologues and human TRIM family proteins against lentiviral production. PLoS ONE. 2011;6(1):e16121.CrossRef Ohmine S, Sakuma R, Sakuma T, Thatava T, Takeuchi H, Ikeda Y. The antiviral spectra of TRIM5alpha orthologues and human TRIM family proteins against lentiviral production. PLoS ONE. 2011;6(1):e16121.CrossRef
8.
go back to reference Tomar D, Singh R. TRIM family proteins: emerging class of RING E3 ligases as regulator of NF-kappaB pathway. Biol Cell. 2015;107(1):22–40.CrossRef Tomar D, Singh R. TRIM family proteins: emerging class of RING E3 ligases as regulator of NF-kappaB pathway. Biol Cell. 2015;107(1):22–40.CrossRef
9.
go back to reference Hatakeyama S. Early evidence for the role of TRIM29 in multiple cancer models. Expert Opin Ther Targets. 2016;20(7):767–70.CrossRef Hatakeyama S. Early evidence for the role of TRIM29 in multiple cancer models. Expert Opin Ther Targets. 2016;20(7):767–70.CrossRef
10.
go back to reference Zhao MX, Ding SG, Liu LN, Wang Y, Zhang J, Zhang HJ, Zhang Y. Predicative value of expression of TrkB and TRIM29 in biopsy tissues from preoperative gastroscopy in lymph node metastasis of gastric cancer. Zhonghua Yi Xue Za Zhi. 2012;92(6):376–9.PubMed Zhao MX, Ding SG, Liu LN, Wang Y, Zhang J, Zhang HJ, Zhang Y. Predicative value of expression of TrkB and TRIM29 in biopsy tissues from preoperative gastroscopy in lymph node metastasis of gastric cancer. Zhonghua Yi Xue Za Zhi. 2012;92(6):376–9.PubMed
11.
go back to reference Qiu F, Xiong JP, Deng J, Xiang XJ. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol. 2015;8(5):5053–61.PubMedPubMedCentral Qiu F, Xiong JP, Deng J, Xiang XJ. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol. 2015;8(5):5053–61.PubMedPubMedCentral
12.
go back to reference Luo S, Shen M, Chen H, Li W, Chen C. Long noncoding RNA TP73AS1 accelerates the progression and cisplatin resistance of nonsmall cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA34a5p. Mol Med Rep. 2020;22(5):3822–32.PubMedPubMedCentral Luo S, Shen M, Chen H, Li W, Chen C. Long noncoding RNA TP73AS1 accelerates the progression and cisplatin resistance of nonsmall cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA34a5p. Mol Med Rep. 2020;22(5):3822–32.PubMedPubMedCentral
13.
go back to reference Zeng SX, Cai QC, Guo CH, Zhi LQ, Dai X, Zhang DF, Ma W. High expression of TRIM29 (ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelialmesenchymal transition in osteosarcoma. Oncol Rep. 2017;38(3):1645–54.CrossRef Zeng SX, Cai QC, Guo CH, Zhi LQ, Dai X, Zhang DF, Ma W. High expression of TRIM29 (ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelialmesenchymal transition in osteosarcoma. Oncol Rep. 2017;38(3):1645–54.CrossRef
14.
go back to reference Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M, Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell. 2009;15(3):207–19.CrossRef Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M, Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell. 2009;15(3):207–19.CrossRef
15.
go back to reference Yimlamai D, Fowl BH, Camargo FD. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63(6):1491–501.CrossRef Yimlamai D, Fowl BH, Camargo FD. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63(6):1491–501.CrossRef
16.
go back to reference Guimei M, Alrouh S, Saber-Ayad M, Hafezi SA, Vinod A, Rawat S, Wardeh Y, Bakkour TM, El-Serafi AT. Inhibition of Yes-Associated Protein-1 (YAP1) enhances the response of invasive breast cancer cells to the standard therapy. Breast Cancer (Dove Med Press). 2020;12:189–99. Guimei M, Alrouh S, Saber-Ayad M, Hafezi SA, Vinod A, Rawat S, Wardeh Y, Bakkour TM, El-Serafi AT. Inhibition of Yes-Associated Protein-1 (YAP1) enhances the response of invasive breast cancer cells to the standard therapy. Breast Cancer (Dove Med Press). 2020;12:189–99.
17.
go back to reference Deng X, Yi X, Deng J, Zou Y, Wang S, Shan W, Liu P, Zhang Z, Chen L, Hao L. ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation. Exp Cell Res. 2019;385(2):111689.CrossRef Deng X, Yi X, Deng J, Zou Y, Wang S, Shan W, Liu P, Zhang Z, Chen L, Hao L. ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation. Exp Cell Res. 2019;385(2):111689.CrossRef
18.
go back to reference Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. 2019;38(30):5890–904.CrossRef Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. 2019;38(30):5890–904.CrossRef
19.
go back to reference Yi X, Deng X, Zhao Y, Deng B, Deng J, Fan H, Du Y, Hao L. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1. Exp Cell Res. 2020;387(2):111804.CrossRef Yi X, Deng X, Zhao Y, Deng B, Deng J, Fan H, Du Y, Hao L. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1. Exp Cell Res. 2020;387(2):111804.CrossRef
20.
go back to reference van Dongen JC, Suker M, Versteijne E, Bonsing BA, Mieog JSD, de Vos-Geelen J, van der Harst E, Patijn GA, de Hingh IH, Festen S, et al. Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC Trial). Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000004313.CrossRefPubMed van Dongen JC, Suker M, Versteijne E, Bonsing BA, Mieog JSD, de Vos-Geelen J, van der Harst E, Patijn GA, de Hingh IH, Festen S, et al. Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC Trial). Ann Surg. 2020. https://​doi.​org/​10.​1097/​SLA.​0000000000004313​.CrossRefPubMed
21.
go back to reference Wang CY, Brown J. Readmissions after pancreatic surgery in patients with pancreatic cancer: does hospital variation exist for quality measurement? Visc Med. 2020;36(4):304–10.CrossRef Wang CY, Brown J. Readmissions after pancreatic surgery in patients with pancreatic cancer: does hospital variation exist for quality measurement? Visc Med. 2020;36(4):304–10.CrossRef
22.
go back to reference Appikonda S, Thakkar KN, Shah PK, Dent SYR, Andersen JN, Barton MC. Cross-talk between chromatin acetylation and SUMOylation of tripartite motif-containing protein 24 (TRIM24) impacts cell adhesion. J Biol Chem. 2018;293(19):7476–85.CrossRef Appikonda S, Thakkar KN, Shah PK, Dent SYR, Andersen JN, Barton MC. Cross-talk between chromatin acetylation and SUMOylation of tripartite motif-containing protein 24 (TRIM24) impacts cell adhesion. J Biol Chem. 2018;293(19):7476–85.CrossRef
23.
go back to reference Mandell MA, Saha B, Thompson TA. The tripartite nexus: autophagy, cancer, and tripartite motif-containing protein family members. Front Pharmacol. 2020;11:308.CrossRef Mandell MA, Saha B, Thompson TA. The tripartite nexus: autophagy, cancer, and tripartite motif-containing protein family members. Front Pharmacol. 2020;11:308.CrossRef
24.
go back to reference Zhou XM, Sun R, Luo DH, Sun J, Zhang MY, Wang MH, Yang Y, Wang HY, Mai SJ. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget. 2016;7(12):13634–50.CrossRef Zhou XM, Sun R, Luo DH, Sun J, Zhang MY, Wang MH, Yang Y, Wang HY, Mai SJ. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget. 2016;7(12):13634–50.CrossRef
25.
go back to reference Sun J, Zhang T, Cheng M, Hong L, Zhang C, Xie M, Sun P, Fan R, Wang Z, Wang L, et al. TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/beta-catenin signaling pathway. J Exp Clin Cancer Res. 2019;38(1):104.CrossRef Sun J, Zhang T, Cheng M, Hong L, Zhang C, Xie M, Sun P, Fan R, Wang Z, Wang L, et al. TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/beta-catenin signaling pathway. J Exp Clin Cancer Res. 2019;38(1):104.CrossRef
26.
go back to reference Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M, Mori M. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 2007;14(9):2543–9.CrossRef Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M, Mori M. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 2007;14(9):2543–9.CrossRef
27.
go back to reference Yang GY, Zhou ZY, Sun RC, Xia YH, Hong JG, Yu MH, Wu GB, Liang JB. Expression of TRIM29 and beta-catenin in non-small cell lung cancer and its clinicopathologic significance. Zhonghua Bing Li Xue Za Zhi. 2011;40(2):109–10.PubMed Yang GY, Zhou ZY, Sun RC, Xia YH, Hong JG, Yu MH, Wu GB, Liang JB. Expression of TRIM29 and beta-catenin in non-small cell lung cancer and its clinicopathologic significance. Zhonghua Bing Li Xue Za Zhi. 2011;40(2):109–10.PubMed
28.
go back to reference Kanno Y, Watanabe M, Kimura T, Nonomura K, Tanaka S, Hatakeyama S. TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem. 2014;116(5):708–12.CrossRef Kanno Y, Watanabe M, Kimura T, Nonomura K, Tanaka S, Hatakeyama S. TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem. 2014;116(5):708–12.CrossRef
29.
go back to reference Lin C, Xu X. YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. Biomed Pharmacother. 2017;95:789–94.CrossRef Lin C, Xu X. YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. Biomed Pharmacother. 2017;95:789–94.CrossRef
30.
go back to reference Chai J, Xu S, Guo F. TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma. Biochem Biophys Res Commun. 2017;488(2):297–302.CrossRef Chai J, Xu S, Guo F. TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma. Biochem Biophys Res Commun. 2017;488(2):297–302.CrossRef
Metadata
Title
E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1
Authors
Xueqiang Deng
Xiaowei Fu
Hong Teng
Lu Fang
Bo Liang
Rengui Zeng
Lian Chen
Yeqing Zou
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03007-w

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.